Recently, Journal of the American Chemical Society (if 14.695), a famous international academic journal, published the latest research results of Professor Xu Hanmei's team of life science and technology of our university, namely "micropeptide Miac innovations HNSCC progress by interacting with aquaporin 2". Li Mengwei, a postdoctoral fellow and Li Xin, a master's student, are the co first authors of the paper, Professor Xu Hanmei is the corresponding author, and China Pharmaceutical University is the first author unit and the first communication unit. Wu Heming, director of Jiangsu stomatological hospital and Dr. Ding Xu also made important contributions to this paper.
In recent years, scientists have found that long non coding RNA (lncrnas, lncrnas) actually contains small open reading frames (ORFs) that can encode micropeptides, which provides a new perspective for proteomics research. At present, there are few reports about the micropeptides encoded by lncrna. In this study, we first found a new endogenous micropeptide, Miac, encoded by lncrna ac025154.2, which can inhibit the proliferation and metastasis of head and neck squamous cell carcinoma in vitro and in vivo. The results of protein mass spectrometry and yeast two hybrid showed that Miac can bind to aquaporin, inhibit the rearrangement of skeleton protein by regulating the expression of sept2 / ITGB4, and finally inhibit the progression of head and neck squamous cell carcinoma. Combined with the RNA SEQ data of 500 TCGA databases and 154 clinical samples, it was confirmed that the expression level of Miac in the head and neck squamous cell carcinoma was significantly lower than that in the adjacent tissues, which was positively correlated with the overall survival rate of the patients, negatively correlated with the clinical pathological stages and regional lymph node metastasis, suggesting that Miac can be used as a potential marker for clinical diagnosis and prognosis of head and neck squamous cell carcinoma.
At the same time, Wang Ying, a postdoctoral fellow of the research group, and Lu Jiqiang, a master's student, were the co first authors. Professor Xu Hanmei, a corresponding author, published the latest research on microRNA molecules in the journal Molecular Therapy nuclear acids (if 5.919). In this study, the exocrine mir-181b-5p, which is derived from esophageal cancer cells, was studied, and the molecular mechanism of its regulation on tumor angiogenesis was analyzed, which is expected to provide new biomarkers and potential drug targets for clinical diagnosis, treatment and prognosis evaluation of esophageal cancer patients.
In addition, in the past three years, Professor Xu Hanmei's team's other research results on the relationship between RNA and tumor were also published in Clin cancer res (Lin C, Zhang s, Xu h *. 2018 Jan 15; 24 (2): 486-498, if 8.911), oncogene (Lin C, Wang y, Xu h *. 2017 SEP 21; 36 (38): 5392-5406, if 6.854), cell death dis (Li m, Han y, Xu h *. 2018 Jan 24; 9 (2): 91, if 5.959) and other magazines.
(contributors: College of life science and technology, authors: Li Mengwei, Wang Ying, Wang Yuheng)
Source: China Pharmaceutical University
Information link?: http://news.cpu.edu.cn/ee/25/c243a126501/page.htm
[disclaimer] part of the information on this platform comes from the Internet. If the copyright of the author is infringed, please contact us in time (Tel: 025-83271227, or leave a message directly on wechat platform), and we will correct or delete it in time.
On the development of pharmacy
"Pharmaceutical progress" magazine is co sponsored by China Pharmaceutical University and China Pharmaceutical Association, and is in charge of the Ministry of education of the people's Republic of China. The purpose of the journal is to reflect the new methods, achievements, progress and trends in the field of pharmaceutical research, with the characteristics of review, review and industry development report, with the focus on the progress of pharmaceutical discipline, technology progress and technical information in each link of new drug research and development. It is a professional media focusing on the frontier of pharmaceutical technology and industry dynamics.
"Pharmaceutical progress" focuses on content planning, strengthening the group's contribution, in-depth excavation, analysis of pharmaceutical information resources, and has initial characteristics in pharmaceutical discipline progress, research ideas and methods, target mechanism discussion, new drug research and development report, clinical drug use analysis, international pharmaceutical frontier, etc.; especially, the content of pharmaceutical information is more forward-looking with the combination of scientific frontier and national strategic needs Authority, timeliness, novelty, systematicness and practicality. According to the latest statistical data, the average download rate of journal articles has been ranked the first in China's medical journals for three consecutive years, with a composite impact factor of 0.760, which has a high impact
The editorial board of pharmaceutical progress is edited by academician Chen Kaixian, chief engineer of national major special chemical medicine. The editorial board is composed of more than 100 influential experts from the government regulatory department of new drug R & D technology chain, university scientific research institutes, pharmaceutical enterprises, clinical hospitals, cros, and financial capital and intellectual property related institutions.
The official website of the editorial department of pharmaceutical progress: www.cpupps.cn; Email: yxjz@163.com; Tel: 025-83271227. Welcome to contribute and subscribe!
● would you like to review the wonderful activities sponsored and co organized by the editorial board of pharmaceutical progress? Please poke here!
11 novel coronavirus pneumonia new hot topics summary, you may want to ask all of you may be here, Miu Xiaohui.
→ interview with pharmacists | persistent and pragmatic, "crystal" seeking perfection -- Interview with Professor Zhang Jianjun and Professor Gao Yuan of China Pharmaceutical University
"Cold tumor" is difficult to treat? Programmable integrated linkage technology makes "cold tumor" hot! - interview with Professor Tu Jiasheng and Associate Professor Sun Chunmeng of China Pharmaceutical University
Interview with pharmacists | lead regenerative medicine to reshape healthy life -- Interview with Dr. Wang Jiaxian, CEO of ELP Regenerative Medicine Technology Co., Ltd
"High end forum of clinical pharmacy construction, development and reform" was held in Chongqing
"Pharmaceutical service model innovation and future pharmacist value embodiment high end forum" opened
→ [style of medicine and coffee] | micro video of CAI Benzhi, director of Pharmacy Department of the Second Affiliated Hospital of Harbin Medical University
[style of medicine] micro video of Qian Yan, deputy director of Pharmacy Department of the Second Affiliated Hospital of Chongqing Medical University
→ [style of medicine] micro video of fan Guorong, director of clinical medicine of the first people's Hospital Affiliated to Shanghai Jiaotong University
→ [style of medicine and coffee] | micro video of Lin Yang, director of Pharmacy Department of Beijing Anzhen Hospital Affiliated to Capital Medical University
→ [drug style] | micro video of Gu Jingtao, marketing director of Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd
→ [style of medicine] micro video of director Kan Lingyan, pharmaceutical department, Shengjing Hospital Affiliated to China Medical University
→ [style of medicine and coffee] | micro video of Lin Yang, director of Pharmacy Department of Beijing Anzhen Hospital Affiliated to Capital Medical University
→ [style of medicine and coffee] | view sharing micro video of Professor Zhao Limei, deputy director of Medical Department of Shengjing Hospital Affiliated to China Medical University
→ [style of medicine and coffee] | micro video of Zhao Zhigang, director of Pharmacy Department of Beijing Tiantan Hospital Affiliated to Capital Medical University
→ [style of medicine and coffee] | micro video of Professor Zhao Qingchun, director of Pharmacy Department of North War area general hospital
→ lead the life science and technology, empower the health industry | directly attack the wonderful scene of the opening ceremony and Summit Forum of Nanjing International Life Health Science and Technology Conference 2019
Leading life science and technology, empowering health industry
Leading life science and technology, empowering health industry
Leading life science and technology, empowering health industry
Successfully held "2019 pharmaceutical practice exchange and visit activity in Xiamen"
Great minds in the field of medicine gathered in Changzhou to discuss the problem of "neck sticking" in the research and development of new anti-tumor drugs?
The "Empowering trip" of overseas Chinese Biomedical elites sponsored by the editorial board of pharmaceutical progress was a complete success!
→ Zhongshan summit 11 innovation projects + 10 professional organizations
The Editorial Committee of pharmaceutical progress gathered in the port city to help Lianyungang biomedical industry innovate in the future!